GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials : Journal of the American Society of Nephrology

Journal Logo

Meta-Analysis

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

Inker, Lesley A.1; Heerspink, Hiddo J. L.2; Tighiouart, Hocine3,4; Levey, Andrew S.1; Coresh, Josef5; Gansevoort, Ron T.6; Simon, Andrew L.1; Ying, Jian7; Beck, Gerald J.8; Wanner, Christoph9; Floege, Jürgen10; Li, Philip Kam-Tao11; Perkovic, Vlado12; Vonesh, Edward F.13; Greene, Tom7

Author Information
JASN 30(9):p 1735-1745, September 2019. | DOI: 10.1681/ASN.2019010007
  • Buy
  • Infographic
  • SDC

Abstract

Copyright © 2019 by the American Society of Nephrology

Full Text Access for Subscribers:

You can read the full text of this article if you:

Access through Ovid